Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection
Ziheng Feng, Zhengde Xie, Lili Xu
Abstract
Respiratory syncytial virus (RSV) is one of the most common viruses leading to lower respiratory tract infections (LRTIs) in children and elderly individuals worldwide. Although significant progress in the prevention and treatment of RSV infection was made in 2023, with two anti-RSV vaccines and one monoclonal antibody approved by the FDA, there is still a lack of postinfection therapeutic drugs in clinical practice, especially for the pediatric population. In recent years, with an increasing understanding of the pathogenic mechanisms of RSV, drugs and drug candidates, have shown great potential for clinical application. In this review, we categorize and discuss promising anti-RSV drug candidates that have been in preclinical or clinical development over the last five years. • The high burden of disease caused by RSV highlights the critical need for effective preventive and therapeutic measures. • New, efficient, and affordable drugs, especially postinfection therapies, to combat RSV infection, are urgently needed. • We categorize and discuss the anti-RSV drugs that have entered clinical development as well as some promising candidates.